图片来源:视觉中国界面新闻记者 |陈杨界面新闻编辑 |谢欣曾经的“PD-1四小龙”之一、做出最早获批的国产PD-1、并最早使国产PD-1在美获批的君实生物如今扮演着“追赶者”的角色。5月29日盘后,君实生物发布公告称,调整2022年定增募投项目“创新药研发项目”中的多个子项目,包括增加对6个、减少对14个子项目的资金投入。其中,变动金额最多的“JS207境内外研发”子项目即是当下创新药领域最热门的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.